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1. Introduction 
Fibronectin is a glycoproteln (MI 440 000) present 
on cell surfaces and in the blood [ 1,2]. It forms com- 
plexes with collagen,gelatin and collagen-derived frag- 
ments [3-51. A region has been identified in tibro- 
nectin that is responsible for its collagen-binding 
activity [6]. This region is located -2/3rds of the 
linear distance from the NH,-terminus of each chain 
in the dimeric molecule. Fibronectin evidently pos- 
sesses, therefore, 2 independent binding sites for 
collagen, one on each chain, enabling it to bivalently 
interact with collagen and to form extended polymers. 
Since Clq, a subcomponent of the first comple- 
ment component Cl, contains a collagen-like fragment 
[7] that competes functionally with collagen [g-13], 
we have investigated whether Clq and/or its collagen- 
like fragment is able to form complexes with tibro- 
nectin and whether such an interaction can be inhibited 
by collagen or by antifibronectin-antibody. Complex 
formation between collagen and fibronectin can be 
completely inhibited by the addition of an antiserum 
to fibronectin [ 141, which suggested that the anti- 
bodies to fibronectin were at least in part directed 
against the collagen-binding site of fibronectin and 
that the affinity of the antibody for fibronectin is 
much higher than that of collagen for fibronectin. 
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2. Materials and methods 
C 1 q was prepared from human serum according to 
[ 151 and further purified using con A-Sepharose [ 161. 
Clq was labeled with rz51 using the chloramine-T 
method [ 17],1 .O mCi Nalz I was used/mg protein. 
Excess labeling reagent was eliminated by gel chroma- 
tography on Sephadex G-25. The collagen-like frag- 
ment of Clq (CLF) was obtained by limited peptic 
digestion [ 181. Purity of the preparation was checked 
by Mr determination and amino acid analysis [ 181. 
CLF was 3H-labeled by acetylation: to 1 mg CLF in 
0.1 M Tris-HCl buffer of pH 9.0 (1 mg CLF/ml) 50 nl 
[ 3H] acetic anhydride in toluene (equivalent to 5 mCi; 
spec. act. 3.85 Ci/mmol; Amersham, batch 49) was 
added dropwise with vigorous stirring. After 30 min 
at room temperature, the solution was dialysed against 
1 .O M NaCl/O.OS M Tris-HCl buffer (pH 7.5) and the 
[ 3H] CLF was then chromatographed on a Sephacryl 
S-300 column (Pharmacia), equilibrated against the 
same buffer. For interaction studies, [3H]CLF was 
dialysed against phosphate-buffered saline of pH 7.2 
(PBS). Plasma fibronectin (cold-insoluble globulin, 
CIG) was purified by affinity chromatography on 
gelatin-Sepharose [3]. CIG was labeled with Na’*‘I 
using 0.5 mCi/mg [14]. 
Human type I collagen was prepared by acidic 
extraction of infant dura mater [ 191. Human collagen 
type II was obtained by limited pepsin digestion of 
infant cartilage after extraction of proteoglycans [20]. 
Human type III collagen was prepared by peptic diges- 
tion of infant skin [21]. Collagens were used in dena- 
turated state (30 min, 60°C). 
Antifibronectin antiserum from sheep was pur- 
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chased from Boehringer Mannheim. Rabbit antifibro- 
nectin serum was a gift. A commercial rabbit antiserum 
raised against human Clq was used (Behring-Werke, 
Marburg; batch 6304 B). Its antiClq and anti-CLF 
titer was determined using passive hemagglutination 
D31. 
Interaction experiments: Labeled C 1 q or CLF was 
incubated with different amounts of fibronectin in 
glass tubes (30 min, 37”C), then antifibronectin was 
added (5 1.11-0.2 ml of the incubation mixture) and 
incubation continued for 30 min at 37°C and 1 h at 
4°C. Goat-anti-rabbit gammaglobulin (0.2 ml) diluted 
1:4, was added (Calbiochem, Luzern) and incubation 
was done at 4’C for 20 h. As controls instead of anti- 
fibronectin and/or goat-anti-rabbit gammaglobulin 
(steps 2,3) PBS was added. The precipitates were cen- 
trifuged(5000Xg,30min,4°C),washed3timeswith 
PBS and counted (for 3H-labelled sediments after dis- 
solution in NaOH). Alternatively, 1: lo-diluted anti- 
tibronectin antiserum (0.2 ml) was incubated with 
increasing amounts of “‘1-labelled fibronectin for 
60 mln at 37°C followed by 20 h at 4°C. In parallel 
analogous experiments were performed in the 
presence of CLF. Precipitated radioactivity was 
determined. 
For solid phase interaction studies polystyrene 
tubes (11 X 70 mm, Nunc, Denmark) were coated with 
C lq by incubation with a PBS-solution containing 
10 pg Clq/ml (1 .O ml/tube) for 3 days at 4°C. After 
washing with cold PBS and incubation with 0.1% 
bovine serum albumin in PBS for 2 h at room temper- 
ature tubes were reacted with 1251-labelled fibronectin 
or with mixtures of collagen (CLF) and ‘%I-labelled 
fibronectin, preincubated for 30 min at 37”C, for 1 h 
at 37°C and 30 min at 4°C. The fiial assay volume 
was 0.5 ml/tube. After incubation, the tubes were 
washed 3 times with PBS and adsorbed radioactivity 
was determined. 
For affinity chromatography cold fibronectin was 
coupled to 25 mg BrCN-activated Sepharose (Phar- 
macia) by incubating with 250 pg protein in 0.25 ml 
buffer (0.5 M NaCl/O.l M NaHCO, (pH 8.0)) for 2 h 
at room temperature. The gel was packed in a Pasteur 
pipette, stoppered with a small plug of cotton wool. 
Clq or [ 3H] CLF solution (1 ml) in PBS was slowly 
passed at room temperature through the gel (5 min). 
In the eluate the remaining protein was determined. 
As control CNBr-activated Sepharose that had been 
reacted with ethanolamine was used. 
3. Results 
[ 3H] CLF was freed of aggregates by gel chroma- 
tography on Sephacryl S-300. The monomeric fraction 
eluting between 190-200 ml was incubated at 10 pg/ 
mlwith unlabeled flbronectin in different molar ratios. 
The influence of adding rabbit antifibronectin serum 
and/or second antibody on the amount of precipitated 
[3H]6LF was studied ([3H]CLF spec. act. 30 X IO6 
dpm/mg). Fig.1 indicates that maximal precipitation 
occurs at a molar ratio [ 3H] CLF: fibronectin = 2: 1, 
47% of total added radioactivity precipitating at this 
molar ratio, if [ 3H] CLF is allowed to interact with 
fibronectin without later additions. The addition of 
antifibronectin antibody (fmal dilution 1:80) nearly 
completely abolishes [ 3H] CLF-precipitation due to 
complex formation with fibronectin, while addition 
of goat-anti-rabbit gammaglobulin alone only results 
in a reduction of [ 3H] CLF precipitation by fibronec- 
tin (17.5% precipitated at 2: 1 molar ratio). Addition 
of normal rabbit serum in the second incubation step 
also caused a reduction in precipitated radioactivity 
(24.7% at 2:l ratio). 
In the case of Clq-fibronectin interaction only a 
small fraction of 12’I-Clq was precipitated by fibro- 
nectin. Thus, with equimolar amounts of Clq and 
fibronectin 1.9% of total added ‘“I-labelled Clq were 
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Fig.1. Precipitation behavior of different [ “H]CLF-fibronec- 
tin mixtures. (0) [ ‘H]CLF + fibronectin; at the second and 
third incubation step PBS was added; (0) step 2, + antifibro- , 
neck antibody; step 3, + goat-anti-rabbit gammaglobulin; 
(A) step 2, + antifibronectin antibody; step 3, + PBS; (A) step 2, 
+ PBS; step 3, + goat-anti-rabbit gammaglobulin; similar to 
this curve: step 2, + normal rabbit serum (not shown; maxi- 
mal precipitation 24.7%). 
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precipitated (control incubation of iZSI-labelled Clq 
alone: 1.2%). This was increased to 2.7% by adding 
antifibronectin antibody in step 2. Addition of anti- 
Cql antiserum, however, completely abolished the 
small ‘*‘I-labelled Clq-fibronectin precipitate formed 
withequimolar amounts of the two proteins. The anti- 
C 1 q serum used displayed a significant reactivity 
towards CLF (passive hemagglutination titer using 
Clqcoated erythrocytes 1: 10 000, using CLF-coated 
erythrocytes 1:2500). The specific activity of the 
1251-labelled Clq used in our experiments was 
330 X 10” dpm/mg. 
To further investigate the relative affinity of anti- 
fibronectin antibody and CLF to fibronectin, anti- 
fibronectin antiserum was incubated with increasing 
amounts of “‘1-labelled fibronectin in the presence 
or absence of CLF (final cont. 25 I.cg/ml). The spe- 
cific activity of our ‘%I-labelled fibronectin was 
45 X JO6 dpm/mg. Fig.2 (rabbit anti-fibronectin 
serum) demonstrates that the characteristic precipita- 
tion behavior of the antiserum towards labeled fibro- 
nectin is not essentially altered in the presence of con- 
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Fig.2. Precipitation characteristics of a rabbit-anti-fibronec- 
tin antiserum (1: lo), influence of CLF (25 Mg/ml); 0.2 ml 
antiserum were Incubated with 0.2 ml fibronectin solution 
in PBS (+0.05% bovine serum albumin): (0) without CLF; 
(0) with CLF. 
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stant amounts of CLF. A reduction of specifically pre- 
cipitated ‘251-labelled fibronectin is, however, observed, 
especially at high antibody excess. Analogous results 
were obtained with commercial sheep antifibronectin 
antiserum. 
The precipitation experiments using labeled Clq 
and cold fibronectin provide no conclusive evidence 
of any significant complex formation between the 
two proteins, therefore an attempt was made to 
demonstrate such an interaction by affmity chroma- 
tography. Sepharose-bound fibronectin was incubated 
with Clq and [3H]CLF to compare the reactivity of 
native Clq and its collagen-like fragment with the 
matrix-bound protein. The results of these experi- 
ments are listed in table 1, showing significant binding 
both of Clq and [3H]CLF to the insolubilized fibro- 
nectin, while adsorption to the control Sepharose was 
negligible. It could be demonstrated that the bound 
[3H]CLF was not eluted by native Clq. 
Finally, we wanted to compare the relative affinity 
of collagens type I, II and III to fibronectin with that 
of CLF and Clq. We used solid phase interaction 
experiments. We incubated Clqcoated polystyrene 
tubes with 1251-labelled fibronectin in the presence of 
increasing amounts of CLF or denatured collagens of 
human origin (table 2). Our results clearly indicate 
that fibronectin-Clq interaction may be significantly 
inhibited by CLF and denaturated collagens, most 
efficiently by type III collagen. The high affinity of 
this collagen to fibronectin was also proven in a pre- 
cipitation experiment, in which even very low relative 
collagen concentrations (molar ratio collagen:CLF = 
1:20) nearly completely inhibited the characteristic 
fibronectin precipitation by CLF (fig.3). 
Table 1 
Interaction of Clq ([ ‘H]CLF) with Sepharoa-bound 
iibronectin 
Parameters determined Fibronectin- 
column 
Control 
column 
Flbronectin coupled @g) 200 - 
Coupling efficiency (%) 80 - 
% Clq aretained by 
column (240 pg added) 48 3 
% [ SH]CLFa retained 
(100 ng added) 62 3 
[ ‘H]CLF eluted by 1 ml 
Clq (240 a/ml) - - 
a Original concentration was 0.6 PM 
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Table 2 
Interaction of labeled fibronectin with Clqcoated polystyrene tubes and its 
inhibition by CLF and denaturated collagens 
Inhibitor % inhibition by 
t&ml) 
CLFa Collagen I Collagen II Collagen III 
1 .o - - 12.4 12.3 
10.0 12.4 20.2 21.3 32.6 
a % inhibition obtained at CLF levels of 20.0,40.0 and 80.0 pg/ml: 39.0,59.8 
and 69 5, respectively. Amount of ‘251-labelled fibronectin bound/tube in the 
absence of an inhibitor: 36 ng (uncoated tube: 17 ng) 
4. Discussion 
Complex formation between fibronectin and the 
collagen-like fragment of C 1 q results in the formation 
of precipitates, suggesting generation of extended lat- 
tice structures as a consequence of bivalent (antibody- 
like) interaction of fibronectin. Addition of small 
amounts of anti-fibronectin antibody even after pre- 
incubation of fibronectin with CLF caused complete 
inhibition of this precipitation. An identical amount 
of non-immune rabbit serum or an amount of second 
antibody equivalent to the first serum added, although 
significantly reducing fibronectin precipitation by 
CLF, did not completely inhibit it. While the effect 
of the non-antifibronectin sera may be attributed to 
Fig.3. Inhibition of W&belled fibionectin precipitation by 
CLF due to addition of denaturated collagen type III. CLF 
(0.1 ml) (100 Mg/ml) + 0.1 ml collagen + 02 ml lZSI-labelled 
fibronectin (50 pg/ml) were incubated for 60 min at 37°C. 
Buffer: PBS + 0.05% bovine serum albumin. 
the competitive action of Clq present in these sera, 
the much stronger interference caused by antifibro- 
nectin serum can be interpreted by assuming that the 
antifibronectin antibodies are at least partially directed 
against the CLF-binding site of fibronectin and that 
they have higher affinity to it than CLF. 
Clq was found less prone to precipitate with fibro- 
nectin. Due to the more bulky structure of Clq the 
formation of extended lattice structures could be less 
favoured in this system. The fact that anti-tibronectin 
enhanced ‘*‘I-labelled Clq precipitation may be 
explained by less complete shielding of determinants, 
in the CLF-binding region and/or by additional incor- 
poration of lz51-labelled Clq into the antigen-anti- 
body complex via conventional complement activation. 
That Clq, while not precipitating with fibronectin, 
significantly interacts with this protein, was demon- 
strated in our affinity chromatography experiments 
using Sepharose-bound fibronectin. This interaction 
occurs via the CLF of Clq, since it may be inhibited 
by CLF. 
The portion of the fibronectin molecule involved 
in complex formation with CLF is likely to be at, or 
near, the collagen-binding region, since the Clq-fibro- 
neck interaction was inhibited by denaturated col- 
lagens. Thus, in the precipitation experiment shown 
in fig.3, we see that small amounts of denatured col- 
lagen type III are sufficient to abolish the characteris- 
tic precipitation of fibronectin by much larger 
amounts of CLF (up to 20-fold molar excess of CLF). 
This correponds quantitatively to the results obtained 
in [22], showing that denatured collagen type III is 
very efficient in ‘saturating’ tibronectin by tbrming 
soluble complexes. 
Since Clq, fibronectin and collagens coexist in 
some in vivo and in vitro situations (fibroblast culture 
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supernatants and fibroblast extracts [ 14,231; in plasma 
and other physiological fluids), it is probable that the 
interactions between these molecules observed by us 
have some physiological implications. Thus, Clq- 
fibronectin interaction could be of major importance 
in reticuloendothelial clearance of Clqcoated immune 
complexes from blood, fibronectin acting as ‘opsonic 
protein’ facilitating ingestion by macrophages. It has 
been shown that plasma fibronectin (CIG) is involved 
in the RES elimination of collagen-coated particles 
[24]. In this context, it may be significant that the col- 
lagen-like region of Clq only appears to be exposed in 
serum after activation of the Cl complex and removal 
of the activated Cir and Cis by Ci-inhibitor [25]. 
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